Fig. 1



IC50 in proliferation assay (nM)
0
200
400
600
800
1000
2
3
6
8
9
10
16
18
20
28
32
34
40
68
104
173
193
277
339
499
590
1240
2680
5000
T47D
MCF7
CAL-120
HCC70
HCC1806
MDA-MB-231
DU4475
Her2+
PIK3CAmut
PTENmut
Her2- & PIK3CAwt

Fig. 2



BT-20
BT-474
T47D
ZR-75-1
MDA-MB468
Normalized cell index
time [h]
DMSO
100 nM Compound A
1000 nM Compound A

Fig. 3




BT-20 (3h)
BT-474 (24h)
ZR-75-1 (24h)
Compound A
DMSO
0.2 µM
1 µM
2 µM
PARP (116 kDa)
cleaved PARP (89 kDa)
GAPDH (37kDa)
MDA-MB468
T47D (24h)
24h
48h
PARP (116 kDa)
cleaved PARP (89 kD
GAPDH (37kDa)

Fig. 4


KPL-4
BT-20
BT-474
T47D
ZR-75-1
MDA-MB231
MDA-MB468
Bcl-2 26 kDa
Mcl-1 40 kDa
Survivin 16 kDa
GAPDH 37 kDa

5

Fig. 5




I
II
III
IV
DMSO
2 µ Compound A
-
-
5µM ABT-737
2 µ Compound A
5 µM ABT-737
c ABT -737 [µM]
c Compound A [µM]
Combination Index
Compound A 0.8 0.6 0.4 0.2
ABT-737 0.2 0.4 0.6 0.8
Combination Effect:
Synergistic
Antagonistic

Fig. 6



1 - DMSO

2 - 0.5 μM Rapamycin

3 - 2 μM compound A

4- 2 μM compound A + 0.5 μM Rapamycin

FIGURE 7

IR spectrum of the compound A




FIGURE 8

Raman spectrum of the compound A




FIGURE 9

UV/VIS spectra of the compound A





FIGURE 10



^{1}H-NMR Spectrum of the compound A

FIGURE 11

^{13}C-NMR Spectrum of the compound A





FIGURE 12

^{13}C-NMR Spectra of the compound A



5

FIGURE 13

Mass Spectrum of the compound A

